Increment Antimicrobial Resistance During the COVID-19 Pandemic: Results from the Invifar Network
Increment Antimicrobial Resistance During the COVID-19 Pandemic: Results from the Invifar Network
复制标题
DOI：
10.1089/mdr.2021.0231
复制
发表时间：
2021-12-06
影响因子：
2.6
通讯作者：
Garza-Gonzalez, Elvira
中科院分区：
文献类型：
--
作者：
Lopez-Jacome, Luis Esau;Fernandez-Rodriguez, Diana;Garza-Gonzalez, Elvira
目的：本研究旨在评估之前和2019冠状病毒病（COVID-19）在墨西哥大流行期间收集的一些关键和高优先级微生物的抗菌药物耐药性变化。方法：我们收集了来自血液，尿液，呼吸道样本以及所有标本的关键和高优先级微生物的抗菌药物敏感性数据，其中病原体可能被认为是病原体。数据被分层并比较了两个时期：2019年与2020年和2019年下半年（大流行前）与2020年下半年相比结果：在2019年第二学期与2020年第二学期的分析中，在血液样本中，苯唑西林耐药性增加红霉素（25.7% vs. 42.8%）和克林霉素（24.8% vs. 43.3%）（p
Aim: This study aims to assess the changes in antimicrobial resistance among some critical and high-priority microorganisms collected previously and during the coronavirus disease 2019 (COVID-19) pandemic in Mexico.Methods: We collected antimicrobial susceptibility data for critical and high-priority microorganisms from blood, urine, respiratory samples, and from all specimens, in which the pathogen may be considered a causative agent. Data were stratified and compared for two periods: 2019 versus 2020 and second semester 2019 (prepandemic) versus the second semester 2020 (pandemic).Results: In the analysis of second semester 2019 versus the second semester 2020, in blood samples, increased resistance to oxacillin (15.2% vs. 36.9%), erythromycin (25.7% vs. 42.8%), and clindamycin (24.8% vs. 43.3%) (p